SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April 2008
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
|
|
|
|
|
210, 1167 Kensington Cr. N.W.
Calgary, Alberta
Canada T2N 1X7 |
|
|
|
|
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Collaborators Present Reovirus Research for
Pediatric Sarcomas at AACR Annual Meeting
CALGARY, AB, April 15, 2008 Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
announced that a poster presentation by Dr. Anders Kolb of the Nemours Center for Childhood Cancer
Research entitled Radiation in Combination with Reolysin for Pediatric Sarcomas was presented
today at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being
held in San Diego, California from April 12-16, 2008.
The combination of REOLYSIN® with radiation is certainly favourable, said Dr. Kolb.
Statistically significant improvements in event-free survival are seen in mice treated with the
combination when compared to either therapy alone.
The poster covers preclinical work using reovirus in combination with radiation in mice implanted
with pediatric rhabdomyosarcoma and Ewings sarcoma tumours. The results demonstrated that the
combination of reovirus and radiation significantly enhanced efficacy compared to either treatment
alone in terms of tumour regression and event-free survival.
We are very pleased to be working with investigators such as Dr. Kolb, said Dr. Matt Coffey,
Chief Scientific Officer of Oncolytics. The work completed by Dr. Kolb and his team supports our
ongoing efforts in our human trials with REOLYSIN®.
The poster will be available on the Oncolytics website today at www.oncolyticsbiotech.com
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication
of the materials presented at this meeting with respect to REOLYSIN®, the Companys
expectations related to the results of trials investigating delivery of REOLYSIN®, and
the Companys belief as to the potential of REOLYSIN® as a cancer therapeutic, involve
known and unknown risks and uncertainties, which could cause the Companys actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of
clinical studies and trials, the Companys ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes to the economic environment.
Investors should consult the Companys quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these forward-looking
statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
|
|
Oncolytics Biotech Inc.
Cathy Ward
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
Tel: 403.670.7377
Fax: 403.283.0858
cathy.ward@oncolytics.ca
|
|
The Equicom Group
Nick Hurst
325, 300 5th Ave. SW
Calgary, AB, T2P 3C4
Tel: 403.538.4845
Fax: 403.237.6916
nhurst@equicomgroup.com
|
|
The Investor Relations Group
Erika Moran
11 Stone St, 3rd Floor
New York, NY 10004
Tel: 212.825.3210
Fax: 212.825.3229
emoran@investorrelationsgroup.com |
-30-